Asthma

Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time

Moderate levels of two outdoor air pollutants, ozone and fine particulate matter, are associated with non-viral asthma attacks in children and adolescents who live in low-income urban areas, a study conducted in the US has found. The study also identifies associations between exposure to the two pollutants and molecular changes in the children's airways during non-viral asthma attacks, suggesting potential mechanisms for those attacks. The observational study, funded by the National Institutes of Health (NIH), US, is one of the first to link elevated levels of specific outdoor air pollutants in particular urban locations to distinct changes in the airways during asthma attacks not triggered by respiratory viruses, according to the investigators. The findings are published in the journal The Lancet Planetary Health. "The strong association this study demonstrates between specific air pollutants among children in impoverished urban communities and non-viral asthma attacks further ...

Pharmaceuticals firm Lupin Ltd on Thursday said it has launched a fixed-dose triple drug combination of Indacaterol, Glycopyrronium and Mometasone for managing asthma. The product launched under the brand name DIFIZMA is being offered as a dry powder inhalation, the company said in a regulatory filing. "DIFIZMA is the only FDC (fixed-dose combination) that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled asthma," it said. The product will help in the management of inadequately controlled asthma by improving lung function, providing better symptom control and reducing exacerbations. The drug will be available in one strength with a fixed-dose to be taken once daily, the company added. Lupin India Region Formulations President Rajeev Sibal claimed that DIFIZMA is a first-of-its-kind novel combination product available in India. It is aimed at catering to the unmet need of patients with inadequately controlled asthma and al

Company says treatment will be affordable and improve lung function of patients

Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma. The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily. "Respiratory is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients. "We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma," Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement. The drug maker is the first company in India to market the FDC of .

AstraZeneca India has received marketing authorisation from the Drugs Controller General of India (DCGI) for use of Fasenra

Drug firm Lupin on Tuesday said it has launched generic Zileuton extended-release tablets - used for the treatment of asthma - in the US market. The product is a generic version of Chiesi USA Inc's Zyflo CR extended-release tablets in the same strength, it added. The company has launched Zileuton extended-release tablets in the strength of 600 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing. According to IQVIA MAT June 2020 data, Zileuton extended-release tablets had an annual sales of approximately USD 40 million in the US, Lupinsaid. The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, it added. Shares of Lupin Ltd closed at Rs957.95per scrip on the BSE, up 0.01 per cent from its previous close.

Asthma does not appear to increase the risk for a person contracting Covid-19 or affect its severity, according to a new research

There's been a run on inhalers, and coronavirus patients like the actor Idris Elba have openly worried about their asthma.

The Center at Coral Springs, Florida, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.

The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added.

A mice treated with "zileuton" experienced a 90% reduction in the formation of leukotrienes

New research furthers understanding of the role microscopic organisms play in overall health

Among those who have a week-long sleeping disorder, the risk increases by 94%

Researchers ruled out asthma in 203 people, most of whom were taking asthma medicine.

Some 13.5 per cent of children had asthma when they enrolled in the study

Cured and processed meat is rich in nitrites, which may have a role in airway inflammation

Risk of allergic diseases increases with the number of food allergies a child might have, say researchers